San Diego, CA -- (SBWIRE) -- 02/06/2017 -- Dimension Therapeutics Inc is under investigation over potential securities laws violations. The investigation was announced for investors in NASDAQ:DMTX shares in connection certain financial statements made by Dimension Therapeutics.

Investors who purchased shares of Dimension Therapeutics Inc (NASDAQ:DMTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Dimension Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Dimension Therapeutics, Inc. is a gene therapy company that is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations.

On January 31, 2017, Dimension Therapeutics Inc (NASDAQ:DMTX) announced preliminary topline safety and early efficacy results of Dimension's multi-center phase 1/2 study of DTX101 for the treatment of adult patients with moderate/severe to severe hemophilia B. DTX101, Dimension's lead AAV candidate, is designed to deliver stable expression of blood clotting Factor IX (FIX) in patients with hemophilia B, a rare genetic bleeding disorder resulting from a deficiency in FIX.

Shares of Dimension Therapeutics Inc (NASDAQ:DMTX) declined from $4.50 per share in January 30, 2017, to $1.90 per share on January 31, 2017.

On February 3, 2017, NASDAQ:DMTX shares closed at $1.90 per share.

Those who purchased shares of Dimension Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com